BioSpace News Archive

Solutions in Critical Care (SCC) has partnered with Nanotronics Health, LLC, to distribute nHale™, a non-invasive respiratory support device authorized for the treatment of COVID-19 patients in the hospital, spaces converted for the treatment of COVID-19 patients, and in the private home. The new agreem

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of 430,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $500,000 USD (approximately $645,000 CAD) (the “Offering”). The proceeds of the Offer

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has completed the purchase of an approximately 44-acre site in Hamilton, Montana, for the construction of a vaccine development and commercial scale manufacturing facilit

All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021

Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (NASDAQ:SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, announced today that Sara Ortwein has been appointed to the Companys Board of Directors effective December 18, 2020.

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020 $33.6 million common stock private investment in public equity (“PIPE”) transaction closes concurrently with the merger

Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) t

Five-week pilot program available to schools across the country to bring surveillance testing to teachers and students at no cost

A2 Biotherapeutics ( www.a2bio.com ), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, in which A2 will continue research and preclinical development of its undisclosed Tmod™ cell therapy candidate

~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~ ~ VALO Study Achieves Primary Endpoint in Phase 2 Open-Label Portion ~ ~ Palvella Plans to Share Results with the U.S. Food and Drug Administration in the First Quarter of 2021 ~